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A method to genetically program mouse hematopoietic stem cells
to develop into functional CD8 or CD4 T cells of defined specificity
in vivo is described. For this purpose, a bicistronic retroviral vector
was engineered that efficiently delivers genes for both  and 
chains of T cell receptor (TCR) to hematopoietic stem cells. When
modified cell populations were used to reconstruct the hemato-
poietic lineages of recipient mice, significant percentages of anti-
gen-specific CD8 or CD4 T cells were observed. These cells ex-
pressed normal surface markers and responded to peptide antigen
stimulation by proliferation and cytokine production. Moreover,
they could mature into memory cells after peptide stimulation.
Using TCRs specific for a model tumor antigen, we found that the
recipient mice were able to partially resist a challenge with tumor
cells carrying the antigen. By combining cells modified with CD8-
and CD4-specific TCRs, and boosting with dendritic cells pulsed
with cognate peptides, complete suppression of tumor could be
achieved and even tumors that had become established would
regress and be eliminated after dendritic cellpeptide immuniza-
tion. This methodology of ‘‘instructive immunotherapy’’ could be
developed for controlling the growth of human tumors and at-
tacking established pathogens.
A lthough the immune system handles most pathogens well, itdoes a poor job of suppressing the growth of tumors. This
phenomenon is not totally understood, but much evidence suggests
that limited numbers of T cells capable of responding to tumor cells,
insufficient avidity of these T cells for tumor antigens, and tolero-
genic attenuation by the tumor contribute to this immunological
failure (1–5). Therefore, a major goal of cancer immunotherapy has
been to generate a large number of highly avid, tumor-specific T
cells that can last in vivo for a long time and resist tolerization (6).
Existing methods focus on reshaping the normal T cell repertoire
and fall into two categories: active immunotherapy, which involves
activating the effectors in the host immune system to inhibit cancer
cell growth and reject tumor (e.g., cancer vaccination) (7, 8), and
passive immunotherapy, which directly provides the host with
effectors to react against cancer (e.g., adoptive transfer of in vitro
expanded or modified anti-tumor T cells) (9–14).
We have developed a different approach to anti-tumor immu-
notherapy that involves programming hematopoietic stem cells
(HSCs) to make T cells of a desired specificity in a mouse.
Conventional T cell receptor (TCR) transgenic mice can be made
via pronuclear injection of prerearranged TCR genes (15). How-
ever, this method offers no opportunity for therapeutic application
in humans. In contrast, HSCs are attractive targets for TCR gene
transfer because of their roles as T cell progenitors, enormous
regeneration capacity, and availability for modification in humans
(16). In this article we describe a method to impart the desired
anti-tumor specificities to the mouse T cell repertoire by delivering
tumor-specific TCR genes into HSCs, followed by adaptive transfer
to generate a continuous stream of anti-tumor T cells in host mice.
Materials and Methods
Mice. C57BL6J(B6) female mice were purchased from Charles
River Breeding Laboratories. RAG1/ mice, OT1 TCR trans-
genic mice, and OT2 TCR transgenic mice were purchased from
The Jackson Laboratory. RAG1OT2 Tg mice were generated by
breeding OT2 Tg mice with RAG1/ mice. All mice were housed
in the California Institute of Technology animal facility in accor-
dance with institute regulations.
MOT1 and MOT2 Retrovirus. The MOT1 and MOT2 constructs were
generated from the MIG retrovirus (17). OT1 and OT2 TCR
cDNAs were kind gifts of F. R. Carbone (University of Melbourne,
Melbourne) and W. R. Heath (The Walter and Eliza Hall Institute
of Medical Research, Melbourne). Retroviruses were made in
HEK293.T cells as described (17).
HSC Isolation, Infection, and Transfer. B6 or RAG1/ female mice
6–8 weeks old were treated with 250 g of 5-fluorouracil per gram
of body weight (Sigma). Five days later, bone marrow (BM) cells
were harvested and cultured for 4 days in RPMI medium 1640
containing 10% FBS with 20 ngml recombinant murine IL-3, 50
ngml recombinant murine IL-6, and 50 ngml recombinant mu-
rine stem cell factor (all from Biosource International, Camarillo,
CA). On days 2 and 3, the cells were spin-infected with MOT1 or
MOT2 retroviruses supplemented with 8 gml polybrene for 90
min at 770 g at 30°C. On day 4 of culture, BM cells were collected
and transferred by tail vein injection into B6 female hosts or
RAG1/ female hosts that had received 1,200 or 360 rads of
whole-body radiation, respectively. Each host received 2–3  106
infected BM cells. BM recipient mice were maintained on the mixed
antibiotic sulfmethoxazole and trimethoprim oral suspension (Hi-
Tech Pharmacal, Amityville, NY) in a sterile environment for 6–8
weeks until analysis or usage for further experiments.
In Vitro T Cell Stimulation and Functional Assays. For antigen dosage
response, cells were cultured at 2 105 cells per well in T cell culture
medium containing ovalbumin (OVA)p257–269 (designated as
OVAp1) at 0–1 gml or OVAp329–337 (designated as OVAp2) at
0–10 gml. Three days later, culture supernatants were collected
and assayed for IL-2, IL-4, or IFN- production by ELISA, and
proliferation was assessed by [3H]thymidine incorporation (17). For
time-course response, cells were stimulated with 0.1gml OVAp1
or 1 gml OVAp2, and the culture supernatants were collected
and assayed for IL-2, IL-4, or IFN- production by ELISA on days
1.5, 2.5, and 3.5. In cytokine proliferation response, cells were
cultured with 10 ngml recombinant murine IL-2, 10 ngml IL-4, or
10 ngml recombinant murine IL-15 (all from BioSource Interna-
tional) for 4 days in the absence of antigen, and proliferation was
assessed by [3H]thymidine incorporation.
Antibodies and FACS Analysis. Fluorochrome-conjugated antibodies
specific for mouse CD4, CD8, CD25, CD69, CD62L, CD44,
TCRV2, and TCRV5.1,5.2 were purchased from BD Pharmin-
gen. Surface staining was performed by blocking with anti-CD16
CD32 (mouse Fc receptor, BD Pharmingen) followed by staining
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with fluorochrome-conjugated antibodies. Intracellular staining of
TCR was preformed by using the CytofixCytoperm Kit from BD
Pharmingen. A FACScan flow cytometer was used for detailed
analysis.
Tumor Challenge of Mice. The tumor cell lines EL.4 (C57BL6, H-2b,
thymoma) and E.G7 (EL.4 cells transfected with the chicken OVA
cDNA) (18) were used for tumor challenge of mice. A total of 5
106 EL.4 or E.G7 cells were injected s.c. into the left flank of the
mice. Tumor size was measured every other day by using fine
calipers (Manostat, Merenschwand, Switzerland) and is shown as
the product of the two largest perpendicular diameters a b (mm2).
Mice were killed when the tumors reached 400 mm2.
Dendritic Cell (DC) Generation, Antigen Pulsing, and Mouse Immuni-
zation. DCs were generated from BM cultures as described by Lutz
et al. (19), with some minor modifications. Briefly, BM cells were
harvested from B6 female mice (6–8 weeks old) and cultured in
10-cm diameter Petri dishes at 2  106 cells per dish in medium
containing granulocyte–macrophage colony-stimulating factor,
with fresh medium feeding on days 3, 6, and 8. On day 9,
nonadherent cells were collected and plated into new 10-cm
diameter Petri dishes at 4–6 106 cells per dish in the presence of
1gml LPS (Sigma). On day 10, nonadherent cells (usually80%
are mature DCs) were collected and washed once with Iscove’s
modified Dulbecco’s media50 mM 2-mercaptoethanol and resus-
pended in 0.8 ml of the same medium containing 100g of OVAp1
(or 100 g of OVAp1 plus 100 g of OVAp2). The cells were then
incubated at 37°C for 3 h with gentle shaking every 30 min. Three
hours later, the OVAp1 or OVAp12-loaded DCs were washed
twice with PBS and used to immunize mice by tail vein injection.
Each mouse received 0.5  106 OVAp-loaded DCs.
Results
Tumor Model. We chose chicken OVA as the model antigen for our
study. OVA is the well characterized target antigen for both a CD8
TCR, OT1 (recognizing OVAp257–269, designated as OVAp1) (20),
and a CD4 TCR, OT2 (recognizing OVAp329–337, designated as
OVAp2) (21), offering us the opportunity to study both the CD8
cytotoxic and CD4 helper arms of antigen-specific T cell immunity.
Construction of Retroviral Vector to Deliver TCR Genes into HSCs. We
used a mouse stem cell virus-based retroviral vector (17) to deliver
TCR genes into HSCs. Coexpression of the two TCR subunits from
the same vector has proved critical because no antigen-specific T
cells were detected when we used a two-vector system reported
previously (17) to infect WT HSCs (data not shown). We achieved
the coexpression by linking cDNAs encoding TCR  and  chains
with an internal ribosome entry site and inserting this into the
retroviral vector under control of the viral LTR promoter (Fig. 1a).
The vectors expressing OT1 or OT2 TCR were designated MOT1
or MOT2 (Fig. 1a). In addition to using HSCs as the target for gene
transfer, this approach has other features that facilitate clinical
application: single-vector gene delivery, small genetic elements
Fig. 1. Imparting thedesiredCD8 cytotoxic orCD4helper
T cell specificity to the mouse T cell repertoire by genetic
modification of HSCs. HSCs from RAG1/ or B6mice were
infectedwithMOT1 orMOT2 retroviruses and transferred
into either RAG1/ (denoted as RAG1MOT1 or RAG1
MOT2) or B6 (denoted as B6MOT1or B6MOT2) recipient
mice, respectively. RAG1/ (denoted as RAG1) or B6 mice
were included as controls. OT1 and OT2 TCRs were de-
tected by costaining of TCR V2 and V5. (a) Schematic
representation of the MOT1 and MOT2 retrovirus con-
structs. IRES, internal ribosomal entry site; WRE, wood-
chuck responsive element. (b) Expression of OT1 or OT2
TCRs in BM detected by intracellular staining. (c) Thymic
development of OT1 or OT2 T cells. (Upper) Thymocyte
expression of OT1 or OT2 TCRs was detected by intracel-
lular staining. (Lower) Distribution of developmental
markers CD4 and CD8 is shown. (d) Detection of mature
OT1 CD8 or OT2 CD4 T cells in periphery.









(TCR  and  cDNAs), and a convenient viral promoter to drive
the expression of transgenes.
Imparting the Desired CD8 or CD4 T Cell Specificity to the Mouse T Cell
Repertoire by Genetic Modification of HSCs. In our first step to test
MOT1 and MOT2, we found that both retroviruses efficiently
mediated functional TCR expression upon infecting peripheral
mouse T cells (Supporting Methods and Fig. 5, which are published
as supporting information on the PNAS web site). We then tested
whether MOT1- and MOT2-mediated expression of TCRs could
program WT HSCs to develop into OT1 and OT2 T cells in vivo.
RAG1/HSCs were included as a control. B6 WT and RAG1/
HSCs were infected with MOT1 or MOT2 viruses and then
transferred into WT mice (denoted B6MOT1 or B6MOT2) or
RAG1/ recipients (denoted RAG1MOT1 or RAG1MOT2).
The recipients were allowed to reconstitute their T cell compart-
ments for 7 weeks before analysis. Some 3–7% of the total BM cells
were transduced (Fig. 1b), including long-term HSCs that expressed
c-kit and Sca-1 (16) (data not shown). The percentage of transduced
HSCs remained constant to 8-month posttransfer and persisted
through a secondary BM transfer (data not shown), indicating that
they maintained their stem cell features of longevity and self-
renewal. Therefore, this genetic method is sufficiently robust to
ensure the maintenance of a transduced HSC population for the
lifetime of the host.
We then analyzed T cell development in thymus. Owing to a lack
of endogenous TCRs, unmodified RAG1/ thymocytes cannot
progress to the CD4CD8 double-positive (DP) stage (22). As
shown in Fig. 1c, thymocytes from RAG1MOT1 and RAG1
MOT2 mice expressed transgenic TCRs and gained the ability to
develop into DP cells, and further into either CD8 or CD4
single-positive T cells. This system displayed a high specificity in the
guidance of T cell development to the expected fate, which was
confirmed by the observation that in the periphery there were only
OT1 monospecific CD8 T cells in RAG1MOT1 mice and only
OT2 monospecific CD4 T cells in RAG1MOT2 mice (Fig. 1d).
In the thymi of B6MOT1 and B6MOT2 mice, we detected
thymocytes expressing transgenic TCRs and observed an augmen-
tation of the CD8 or CD4 single-positive T cell compartment in
comparison with WT animals (Fig. 1c). Further analysis of periph-
eral T cells showed that in a representative experiment 25% of the
total peripheral CD8 T cells in B6MOT1 expressed OT1 TCR and
8% of the total peripheral CD4 T cells in B6MOT2 mice expressed
OT2 TCR, with no leakage into the other T cell compartment (Fig.
1d). In numerous experiments, we achieved an average of 20%
(ranging from 15% to 30%) of the total peripheral CD8 T cells in
B6MOT1 mice carrying the OT1 TCR specificity, and an average
of 8% (ranging from 5% to 10%) of the total peripheral CD4 T
cells carrying the OT2 TCR specificity. This high percentage of
antigen-specific T cells remained constant for 8 months posttrans-
fer. Therefore, retrovirus-mediated expression of TCR cDNAs in
WT HSCs can stably generate a significant population of T cells
with the desired features and specificity. In natural conditions, this
percentage can be achieved only by clonal expansion of a few
high-affinity T cell clones after strong immune stimulation (23).
Comparison of the Efficacy of Generating OT2 T Cells in RAG1MOT2
Mice and the Conventional RAG1OT2 Tg Mice. To evaluate the
efficacy of our method for instructing the host to generate antigen-
Fig. 2. Comparison of the efficacy of
generating OT2 T cells in RAG1MOT2
mice and the conventional RAG1OT2
Tg mice. OT2 TCRs were detected by
costaining of TCR V2 and V5. (a) OT2
TCR expression in BM as measured by
intracellular staining. (b) OT2 TCR ex-
pression and T cell development in thy-
mus (Thy). T cell development was as-
sessed by distribution of developmental
markers CD4 and CD8. OT2 TCR expres-
sion at each development stage is
shown. DN, double negative; DP, dou-
ble positive; SP, single positive. (c) TCR
expression in peripheral OT2 T cells.
Mice were immunized with OVAp2 an-
tigen and complete Freund’s adjuvant
for 6days. Both intracellular and surface
expressions of OT2 TCR was measured.
(d) Total OT2 T cells in unchallenged
(naı¨ve) and immunized mice.
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specific T cells in vivo, we performed a detailed comparison
between RAG1MOT2 mice and conventional RAG1OT2 Tg
mice (Fig. 2). The RAG1/ background offered a clean system for
our intended study, because of the lack of endogenous TCR
expression (22). Surprisingly, TCR  and  chain expression
patterns in the thymocytes of RAG1MOT2 mice closely resem-
bled the  chain expression in RAG1OT2 Tg mice that is under
control of the endogenous TCR promoter and enhancers (21) (Fig.
2b). The mature OT2 T cells recovered from the periphery of the
two kinds of mice were comparable, although there was more
heterogeneity of TCR expression in the OT2 T cells from RAG1
MOT2 mice (Fig. 2c). A similar magnitude of antigenic response
was observed when we immunized the animals with OVAp2
antigen (Fig. 2d).
Characterization of the Antigen-Specific CD8 and CD4 T Cells Gener-
ated by Genetic Programming of WT HSCs. This methodology of
programming of HSCs could, with high efficacy, continuously
generate in the host a large population of T cells directed against a
desired antigen. We then focused our attention on the functionality
of the T cells generated by this method. As shown in Fig. 3a, OT1
T cells harvested from B6MOT1 mice displayed the canonical
naı¨ve phenotype of CD8 T cells: CD25CD69CD62LhighCD44low.
Upon stimulation with OVAp1 in vitro, these OT1 T cells re-
sponded vigorously as measured by proliferation and IFN- pro-
duction, with a magnitude comparable to the response of transgenic
OT1 T cells obtained from conventional OT1 TCR transgenic mice
(20) (Fig. 3b). FACS analysis showed that the activated OT1 T cells
exhibited the typical effector cytotoxic T cells phenotype:
CD25CD69CD62LlowCD44high (Fig. 3a).
We then tested the ability of these OT1 T cells to generate and
maintain CD8 T cell memory by adoptive transfer of in vitro-
activated OT1 cytotoxic T cell to host mice; we used this approach
because continuous generation of naı¨ve OT1 T cells makes it
difficult to directly analyze memory formation in B6MOT1 mice.
Sixteen weeks after transfer, long-lived OT1 T cells were detected
in the hosts, which displayed the memory phenotype
(CD25CD69CD62LhighCD44high) (Fig. 3a). These cells showed a
stronger and faster response to antigen stimulation when compared
with naı¨ve OT1 T cells (Fig. 3c). Furthermore, they proliferated
upon cytokine stimulation, which is a unique feature of memory T
cells (24) (Fig. 3c).
Similar results were obtained for OT2 CD4 T cells (Fig. 6, which
is published as supporting information on the PNAS web site).
Thus, OT1 and OT2 T cells generated by our method are fully
functional and normal in all aspects we evaluated. In particular, the
ability of these T cells to generate and maintain long-term memory
makes the method attractive for immunotherapy.
In Vivo Constitution of Anti-Tumor T Cell Immunity. The therapeutic
potential of this method was tested in the E.G7 mouse tumor model
(18). OVA serves as the tumor antigen in this model, allowing us
to study either anti-tumor cytotoxic T cell immunity in B6MOT1
mice, anti-tumor helper T cell immunity in B6MOT2 mice, or the
combination of both arms in B6MOT1MOT2 mice (B6 mice
receiving both MOT1- and MOT2-transduced WT HSCs) (Fig. 4a)
(25). Suppression of syngenic tumor growth was studied by using
the following protocol: B6MOT1, B6MOT2, and B6
MOT1MOT2 mice were allowed to reconstitute their T cell
compartment over 8–10 weeks after receiving retroviral transduced
HSCs. E.G7 tumor cells were then injected s.c., and EL.4 tumor
cells were used as a control (18). To evaluate the effects of peptide
immunization, half of the experimental groups were immunized by
using DCs loaded with OVAp1 (DCOVAp1) 4 days after tumor
injection. Four mice were used in each treatment group, and the
experiments were performed three times.
The results of one representative experiment are shown in Fig.
4b. Compared with the B6 control, significant tumor suppression
was observed in B6MOT1 mice, with complete suppression in
50% of the mice. No recurrence of tumors was observed as long as
the experiments ran (up to 200 days). For the other 50%, tumor
growth was suppressed up to 18 days but eventually progressed. We
recovered E.G7 tumor cells from these mice and found they were
still recognized by naı¨ve OT1 T cells (Fig. 7, which is published as
supporting information on the PNAS web site), excluding the
possibility of ‘‘epitope escape’’ by OVA antigen mutation. When we
analyzed the OT1 cells recovered from the tumor-bearing mice, we
found they could no longer respond to OVAp1 antigen stimulation
in vitro, as measured by IFN- production (Supporting Methods and
Fig. 8 a and b, which is published as supporting information on the
Fig. 3. Characterization of the OT1 CD8 T cells generated by genetic pro-
gramming ofWTHSCs. OT1 T cells harvested fromB6MOT1mice [denoted as
OT1(BMT), where BMT is BM transfer] 8 weeks after HSCs transfer were
considered to be naı¨ve. They were stimulated with OVAp1 in vitro for 3 days
to generate effector OT1 T cells, which were then transferred into host mice
for memory study. (a) Patterns of surface activation markers on OT1(BMT) T
cells at the naı¨ve, effector, or memory stages. (b) Functional analysis of the
naı¨ve OT1(BMT) T cells (■). Proliferation and IFN- production in response to
OVAp1 stimulation are shown. The responses were comparedwith OT1 T cells
from the conventional OT1 TCR transgenic mice, denoted as OT1(Tg) (F). B6
spleen cells were included as negative control (B6 Ctrl, Œ). Equal numbers of
OT1(BMT) and OT1(Tg) T cells were used in all of the experiments. (c) Func-
tional analysis of memory OT1(BMT) T cells [denoted as OT1(BMT, Memory),
■]. Dosage response (Left) and time-course response (Center) to OVAp1
stimulation as measured by IFN- production and proliferation response to
cytokine stimulation (Right) are shown. The responses were compared with
thoseof thenaı¨veOT1(BMT) T cells [denotedasOT1(BMT,Naı¨ve),F). B6 spleen
cells were included as a negative control (B6 Ctrl, Œ). Equal numbers of
OT1(BMT, Memory) and OT1(BMT, Naive) T cells were used in all of the
experiments.









PNAS web site). These anergic OT1 T cells displayed a surface
phenotype that resembled naı¨ve T cells but with higher CD44
expression (Fig. 8c), indicating that they had encountered tumor
antigen. Interestingly, total T cells still responded to anti-CD3
stimulation (data not shown), suggesting the existence of an active
antigen-specific tumor tolerogenic mechanism (26). Similar results
were obtained for B6MOT2 tumor-bearing mice (Fig. 9, which is
published as supporting information on the PNAS web site),
suggesting that tolerogenic mechanisms act on both anti-tumor
cytotoxic and helper T cells.
We tested whether DC-based peptide immunization could en-
hance OT1 T cell function and thus improve their anti-tumor
activity (27). As hoped, this strategy thoroughly suppressed tumor
growth in all of the B6MOT1 mice (Fig. 4b).
Interestingly, we also observed significant tumor suppression in
B6MOT2 mice (Fig. 4b) despite the fact that unlike OT1 T cells
OT2 T cells cannot directly recognize E.G7 tumor cells because of
their lack of MHC II expression (Fig. 10, which is published as
supporting information on the PNAS web site). The possible
mechanism in this case would be cross-presentation of tumor
antigens by the host-derived antigen-presenting cells (25). Even
more strikingly, when we immunized B6MOT2 mice with DC
OVAp1 complete suppression of tumor growth was observed in all
of the mice (some tumors grew up to a barely detectable size but
soon regressed) (Fig. 4b). This series of experiments indicated that
the CD4 anti-tumor T cells could provide essential help for the
endogenous cytotoxic T cell to mount an anti-tumor response,
regardless of whether they can recognize the tumor directly or not.
Fig. 4. In vivo constitution of anti-
tumor T cell immunity. E.G7 mouse
tumor model was used. Tumor size
is shown as the product of the two
largestperpendiculardiametersa
b (mm2). Each line represents one
mouse. Four mice were included in
each group, and experiments were
performed three times. Results
from one representative experi-
ment are shown. (a) Constitution in
mouse of both arms of anti-tumor T
cell immunity. FACS staining
showed the detection of mature
OT1 CD8 and OT2 CD4 T cells in the
spleen of B6MOT1MOT2 mice
(B6 mice receiving both MOT1- and
MOT2-transduced WT HSCs). (b)
Suppression of syngenic tumor
growth by in vivo constitution of
anti-tumor T cell immunity. EL.4
and its OVA-expressing derivative,
E.G7, were the two mouse tumor
types examined. DCOVAp1, DCs
loaded with OVAp1. (c) Eradication
of established solid tumors by in
vivo constitution of both arms of
anti-tumor T cell immunity. E.G7 tu-
mor cells were used. DCOVAp12,
DCs loaded with both OVAp1 and
OVAp2.
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As expected, we observed a combinatorial tumor suppression
effect in B6MOT1MOT2 mice, as exhibited by a slower tumor
growth in mice even when the tumor broke through (Fig. 4b).
DCOVAp1 immunization totally suppressed tumor growth in all
of the mice (Fig. 4b).
Importantly, peptide immunization did not work for B6 control
mice, and in all experimental groups challenged with control tumor
EL.4, the tumors grew up at a similar rate regardless of immuni-
zation, confirming that suppression of E.G7 tumor growth was
tumor antigen-specific and mediated by the engineered anti-tumor
CD8 andor CD4 T cells (Fig. 4b).
We further extended the idea of combining the two arms of
anti-tumor T cell immunity with the aim of eradicating an estab-
lished large vascularized solid tumor. Physiologically, tumors
achieve growth by initially overcoming the host’s anti-tumor im-
muno-surveillance and then constantly tolerizing the anti-tumor T
cells in the host (5). We devised a protocol to mimic these processes:
mice in which E.G7 tumors grew despite the presence of anti-tumor
CD8 (B6MOT1) or both anti-tumor CD8 and CD4 T cells
(B6MOT1MOT2) were immunized with one dose of DCs
loaded with both OVAp1 and OVAp2 (denoted as DC
OVAp12), at the time when their tumors reached 30 mm2 [18 days
after tumor challenge, tumors extant for this duration and with this
size are considered to be long-term established tumors (26)]. As
depicted in Fig. 4c, the tumors in B6MOT1 mice receiving
immunization were suppressed for 10 days but then grew, reaching
400 mm2 in 50 days. In contrast, tumors in B6MOT1MOT2
mice shrank after the immunization and were not longer detectable
within 12 days; no tumor recurrence was observed for as long as
the experiments ran (200 days). These results demonstrated that
established solid vascularized tumors could be eradicated by pro-
viding both the CD8 and CD4 arms of anti-tumor T cell immunity
combined with appropriate peptide immunization to boost the
responses of both arms.
Discussion
We have developed an effective method representing a unique
direction for T cell immunotherapy. It combines stem cell therapy,
gene therapy, and immunotherapy to guide the host to develop, in
vivo, a large population of antigen-specific T cells and thus could be
called instructive immunotherapy. Previous T cell immunotherapy
methods focused on manipulating the existing T cell repertoire and
fell into two categories: active expansion of the antigen-specific T
cells in vivo by immunization and passive (adoptive) transfer of in
vitro expanded T cells (8, 11). These methods rely on massive
expansion of the few antigen-specific T cells, which is usually a
demanding task and not always successful (5, 11). Furthermore,
antigen-specific T cells expanded from an individual’s T cell rep-
ertoire cannot be readily transferred to others because of the risk
of severe graft-versus-host disease (28). TCR gene transfer avoids
these issues. Recently, several groups showed that retrovirus-
mediated expression of TCR genes in peripheral T cells could
endow them with the desired specificity (29, 30). However, such T
cells present certain challenges: they are activated mature cells that
have already expressed an endogenous TCR of the unknown
specificity; their effector function may be restricted by the condi-
tions under which they are activated in vitro; and it is unclear how
long they persist in vivo (31).
Our method shows promising results in the E.G7 mouse tumor
model, implying its therapeutic potential for treating cancers. The
OVA tumor antigen in this model represents a category of ‘‘non-
self’’ tumor antigen including cancer testes antigens and antigens
encoded after genetic alterations or encoded by alternative
atypical transcripts (32). ‘‘Self’’ tumor antigens are more common
(32). Despite the concern that T cells recognizing these antigens
may be subjected to self-tolerance mechanisms, peripheral high-
affinity T cell clones specific for such tumor antigens are observed
and have proved their therapeutic potential in various animal
models and clinical trials (9, 32). TCR genes of such T cell clones
could be handled as we describe here to generate tumor-specific T
cell immunity in vivo.
Our method can be easily extended to generate T cells targeting
multiple epitopes of the antigen, thus countering ‘‘epitope escape’’
by antigen mutations (33). It might also be extended to engineering
the B cell receptor on B cells, allowing the cells to secrete antibodies
of predefined specificity. Therefore, instructive immunotherapy has
the potential to establish in vivo a lifelong ‘‘complete’’ adaptive
immunity (including CD8 cytotoxic T cell, CD4 helper T cell, and
B cell arms) to target any pathogens where antigens and the cognate
TCRB cell receptors are known (6, 34). In addition, this method
could be used for rapid and efficient analysis of such problems as
the development and life history of antigen-specific T cells and in
vivo anti-tumor T cell response and tolerance, providing a useful
tool for basic T cell studies.
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